News

Morningstar1mon
BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia ...
Preclinical results with BFB-101 have demonstrated promising activity and safety (1). The Phase 1/2 clinical trial is a single-center open-label study with a primary objective to assess the safety ...
PharmiWeb29d
BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia ...
Preclinical results with BFB-101 have demonstrated promising activity and safety (1). The Phase 1/2 clinical trial is a single-center open-label study with a primary objective to assess the safety and ...